Croma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast

Saypha® injectables to launch in the U.S. under the Obagi Medical brand, expanding global reach of Croma's science-driven aesthetic solutions

LEOBENDORF, Austria, July 23, 2025 /PRNewswire/ -- Croma-Pharma GmbH, a global leader in minimally invasive aesthetic medicine, today announced the acquisition of Novaestiq Corp. by Waldencast plc (Nasdaq: WALD). Novaestiq, a joint venture between Croma-Pharma and Gore Range Capital, is the company behind the innovative Saypha® ChIQ™ and Saypha® MagIQ™ injectable hyaluronic acid gels, which are set to launch in the U.S. under the Obagi Medical brand.

Read more at prnewswire.com